ARTIFICIAL INTELLIGENCE
FOR DRUG DISCOVERY,
BIOMARKER DEVELOPMENT &
AGING RESEARCH
FOR DRUG DISCOVERY,
BIOMARKER DEVELOPMENT &
AGING RESEARCH
Our Mission is to extend healthy longevity through innovative AI solutions for drug discovery and aging research.
We aspire to be a leader in the field of deep learning for drug discovery, personalized healthcare, and anti-aging interventions.
AI Pharma Pipeline
We developed a comprehensive drug discovery engine, which utilizes millions of samples and multiple data types to discover signatures of disease and identify the most promising targets for billions of molecules that already exist or can be generated
de novo with the desired set of parameters.
de novo with the desired set of parameters.
Integrated top-down and bottom-up target ID
and drug discovery pipelines
and drug discovery pipelines
Pharmaceutical Pipeline Leads
Nutraceutical Pipeline Leads
Services & Collaborations
We provide services to academia, pharmaceutical and cosmetics companies:
- Advanced deep learning solutions
- Custom drug discovery engines
- Custom biomarkers discovery
- New tools for aging research
Bridging the pharmaceutical
and consumer industries
and consumer industries
Awards & Recognition
We will provide customers with the industry-leading services, based
on our extensive experience and proven track-record in innovative
computational technology
on our extensive experience and proven track-record in innovative
computational technology
Nvidia Top 5
AI Companies for Social Impact
Nvidia GTC 2015 Finalist
Deep Learning for Drug Discovery
Most Promising Company
at the Personalized Medicine World Conference 2015 in Palo Alto, CA
106 Artificial Intelligence Startups In Healthcare
From Virtual Nurses To Drug Discovery: 106 Artificial Intelligence Startups In Healthcare
Frost & Sullivan
Best Practices Award 2018
Best Practices Award 2018
Technology leadership in artificial intelligence for drug discovery and biomarker development, academic excellence, extensive collaborations with pharmaceutical and consumer companies, novel methods of attracting top talent, and increasing global reach have allowed Insilico Medicine to build a credible and sustainable business model in the nascent longevity biotechnology industry," noted Neelotpal Goswami.
"In recognition of its pioneering research and ability to introduce novel products and solutions for age management, Frost & Sullivan is pleased to present it with the 2018 Technology Innovation Award".
"In recognition of its pioneering research and ability to introduce novel products and solutions for age management, Frost & Sullivan is pleased to present it with the 2018 Technology Innovation Award".
Videos about Insilico Medicine
Pioneers'18 - Artificial Intelligence for Healthy Longevity
2018 AI 100 Startup: Insilico
Geroprotect Partnership Between Life Extension and Insilico Medicine
About Insilico Medicine
Two Minute Papers: Insilico Medicine
Chemistry AI
Some of Our Current Projects
Insilico Medicine is committed to transforming the pharmaceutical industry with next-generation artificial intelligence.
We are developing new tools for drug discovery and repurposing, biomarker development and pursuing novel strategies
for rapid validation. Our projects combine advances in genomics, big-data analysis, deep learning and reinforcement learning.
We are developing new tools for drug discovery and repurposing, biomarker development and pursuing novel strategies
for rapid validation. Our projects combine advances in genomics, big-data analysis, deep learning and reinforcement learning.
Over 150 Academic
and Industry Collaborators Worldwide
and Industry Collaborators Worldwide
We have a great pleasure to work with the leading companies and institutions
to provide next-level solutions for drug discovery and biomarker development.
to provide next-level solutions for drug discovery and biomarker development.
Recent Deals
Our News
Check out our latest news.
Insilico Medicine, a Baltimore-based next-generation artificial intelligence company specialized in the application of deep learning for target identification, drug discovery and aging research, announced that it has entered into a collaboration agreement with WuXi AppTec, a leading global pharmaceutical and medical device open-access capability and technology platform company.
A ranking of the 100 most promising private artificial intelligence companies in the world
Insilico Medicine collaborates with Neuromation. The recent collaboration on the 3D representations of the molecular structures for GANs.
Insilico Medicine, a company specializing in the application of next-generation artificial intelligence for drug discovery, biomarker development and aging research, announces the presentation of its CEO, Alex Zhavoronkov, at the Pioneers 18 Conference, May 25, 2018, Vienna, Austria.
Insilico Medicine announces the presentation of its Africa AI, Blockchain and Longevity Consultant, Iraneus Ogu, at the KMA 46th Annual Scientific Conference, April 21, 2018, Mombasa, Kenya.
Oct. 30, 2017, London, UK: Biogerontology Research Foundation (bg-rf.org.uk) Chief Science Officer, Dr. Alex Zhavoronkov and Biogerontology Research Foundation Advisor and Head of Business Development for Juvenescence …
Insilico Medicine, a leader in the field of artificial intelligence, will present at the Singularity University Exponential Medicine Program in San Diego on Wednesday November 8 in Session XVIII - Future of Pharma
Insilico Medicine will present at The World Congress on Targeting Metabesity in London, UK on Tuesday, Oct. 31 in Session VIII: Are New Business Models Needed?
Team
Our team is formed of bioinformatics, computational and structural biology experts, experienced medicinal chemists and deep learning engineers, who work with massive biomedical data and practical problems in drug discovery.
Alex Zhavoronkov, PhD
CEO
Qingsong Zhu, PhD
COO
Alex Aliper
President of EMEA
Marine Bozdaganyan, PhD
Head of Medicinal Chemistry
Ivan Ozerov, PhD
Director, Drug Discovery
Quentin Vanhaelen, PhD
Director, Virtual Human Project
We have 45 scientists hired through hackathons and competitions worldwide in the US, UK, Poland, Belgium, South Korea, Taiwan, Africa and Russia.
Scientific Advisory Board
Charles Cantor, PhD
ex-Director of the Human Genome Project and the Center for Advanced Biotechnology at Boston University
Michael Levitt, PhD
2013 Nobel Laureate (Chemistry) Professor, Stanford University
Bud Mishra, PhD
Professor of computer science at Courant Institute, professor of biology at Mt. Sinai School of Medicine and NYU School of Medicine
Donald Small, MD, PhD
Director of pediatric oncology at the Johns Hopkins Kimmel Cancer Center
Yuri Nikolsky, PhD
Co-founder, GeneGo, ex-VP Thomson Reuters Director, Skolkovo Found
Kristen Fortney, PhD
CEO, BioAge.
Postdoctoral fellow of Ellison Medical Foundation/American Federation for Aging Research at Stanford University
Postdoctoral fellow of Ellison Medical Foundation/American Federation for Aging Research at Stanford University
Alexey Moskalev, PhD
Professor at Syktyvkar State University
Head of the laboratory of Molecular radiobiology and gerontology at the Institute of biology of Komi Science Center of Ural division of RAS
Head of the laboratory of Molecular radiobiology and gerontology at the Institute of biology of Komi Science Center of Ural division of RAS
Ulrich Muehlner, PhD
Founder at GrowthCube Partners
Previously Director Global Corporate Strategy at Novartis and with The Boston Consulting Group (BCG)
Previously Director Global Corporate Strategy at Novartis and with The Boston Consulting Group (BCG)
OUR LATEST PUBLICATION
Molecular Pharmaceutics, 23 March 2018
Our Publications
"Bifunctional immune checkpoint-targeted antibody-ligand traps that simultaneously disable TGFβ enhance the efficacy of cancer immunotherapy". Nature Communications(2018).
"In silico Pathway Activation Network Decomposition Analysis (iPANDA) as a method for biomarker development." Nature Communications (2016).
"In silico Pathway Activation Network Decomposition Analysis (iPANDA) as a method for biomarker development." Nature Communications (2016).
"Entangled Conditional Adversarial Autoencoder for de Novo Drug Discovery". Molecular pharmaceutics (2018)
"Adversarial Threshold Neural Computer for Molecular de Novo Design". Molecular pharmaceutics (2018)
"3D Molecular Representations Based on the Wave Transform for Convolutional Neural Networks ". Molecular pharmaceutics (2018).
"Deep learning applications for predicting pharmacological properties of drugs and drug repurposing using transcriptomic data." Molecular pharmaceutics (2016).
"Applications of deep learning in biomedicine." Molecular pharmaceutics (2016).
"Adversarial Threshold Neural Computer for Molecular de Novo Design". Molecular pharmaceutics (2018)
"3D Molecular Representations Based on the Wave Transform for Convolutional Neural Networks ". Molecular pharmaceutics (2018).
"Deep learning applications for predicting pharmacological properties of drugs and drug repurposing using transcriptomic data." Molecular pharmaceutics (2016).
"Applications of deep learning in biomedicine." Molecular pharmaceutics (2016).
"Residual γH2AX foci induced by low dose x-ray radiation in bone marrow mesenchymal stem cells do not cause accelerated senescence in the progeny of irradiated cells". Aging (2017).
"Towards natural mimetics of metformin and rapamycin". Aging (2017).
"A review of the biomedical innovations for healthy longevity". Aging (2017).
"Deep biomarkers of human aging: Application of deep neural networks to biomarker development." Aging (2016).
"In search for geroprotectors: in silico screening and in vitro validation of signalome-level mimetics of young healthy state." Aging (2016).
"Towards natural mimetics of metformin and rapamycin". Aging (2017).
"A review of the biomedical innovations for healthy longevity". Aging (2017).
"Deep biomarkers of human aging: Application of deep neural networks to biomarker development." Aging (2016).
"In search for geroprotectors: in silico screening and in vitro validation of signalome-level mimetics of young healthy state." Aging (2016).
"Vive la radiorésistance!: converging research in radiobiology and biogerontology to enhance human radioresistance for deep space exploration and colonization". Oncotarget (2018).
"Use of deep neural network ensembles to identify embryonic-fetal transition markers: repression of COX7A1 in embryonic and cancer cells". Oncotarget (2018).
"Converging blockchain and next-generation artificial intelligence technologies to decentralize and accelerate biomedical research and healthcare" Oncotarget (2018).
"γH2AX, 53BP1 and Rad51 protein foci changes in mesenchymal stem cells during prolonged X-ray irradiation". Oncotarget (2017).
"The cornucopia of meaningful leads: Applying deep adversarial autoencoders for new molecule development in oncology". Oncotarget (2017).
"Cancer megafunds with in silico and in vitro validation: accelerating cancer drug discovery via financial engineering without financial crisis". Oncotarget (2016).
"A method for predicting target drug efficiency in cancer based on the analysis of signaling pathway activation." Oncotarget (2015).
"Use of deep neural network ensembles to identify embryonic-fetal transition markers: repression of COX7A1 in embryonic and cancer cells". Oncotarget (2018).
"Converging blockchain and next-generation artificial intelligence technologies to decentralize and accelerate biomedical research and healthcare" Oncotarget (2018).
"γH2AX, 53BP1 and Rad51 protein foci changes in mesenchymal stem cells during prolonged X-ray irradiation". Oncotarget (2017).
"The cornucopia of meaningful leads: Applying deep adversarial autoencoders for new molecule development in oncology". Oncotarget (2017).
"Cancer megafunds with in silico and in vitro validation: accelerating cancer drug discovery via financial engineering without financial crisis". Oncotarget (2016).
"A method for predicting target drug efficiency in cancer based on the analysis of signaling pathway activation." Oncotarget (2015).
"The Evaluation of Geroprotective Effects of Selected Flavonoids in Drosophila melanogaster and Caenorhabditis elegans". Frontiers Pharmacology (2017).
"Machine Learning on Human Muscle Transcriptomic Data for Biomarker Discovery and Tissue-Specific Drug Target Identification". Frontiers in Genetics (2018).
"Machine Learning on Human Muscle Transcriptomic Data for Biomarker Discovery and Tissue-Specific Drug Target Identification". Frontiers in Genetics (2018).
Special issue in American Chemical Society's Molecular Pharmaceutics mostly dedicated to GANs and molecules
Generative adversarial networks and deep reinforcement learning techniques are propagating into the many areas of pharmaceutical R&D, learning and augmenting human abilities.
Upcoming Conferences
Press About Us
June 12, 2018
AI And Biotech Companies In The East And West Invest In Combating Aging
Insilico Medicine, a Baltimore-based next-generation AI company specializing in the application of deep learning for target identification, drug discovery and aging research, yesterday announced a collaboration agreement with WuXi AppTec...
Read more
June 11, 2018
With strategic investment, Insilico Medicine is using deep learning to defeat aging
Every once in a while, you meet an entrepreneur who is both fully present, but also has a head full of dreams. That was my experience meeting and hosting Alex Zhavoronkov, the founder and CEO of Insilico Medicine, a few weeks ago in Vienna at the Pioneers conference...
Read more
April 23, 2017
Nvidia identifies the top 5 AI startups for social impact
Nvidia is on a quest to find the best "social impact" artificial intelligence startups as part of a program called Nvidia Inception, which is screening more than 600 entrants to cull the best AI startups in three big categories.
Read more
March 14, 2017
Here's How Pharma Is Using AI Deep Learning To Cure Aging
In 2011, scientists made one of the most important discoveries in the history of AI development. They found that graphics processing units (GPUs) are far better at simulating biological learning than central processing units (CPUs).
Read more
July 26, 2017
British billionaire Jim Mellon and high-profile partners roll the dice
on an anti-aging upstart
on an anti-aging upstart
When British billionaire Jim Mellon wants to map out an investment strategy, he likes to write a book first. Out of that process came his most recent work — Juvenescence: Investing in the Age of Longevity.
Read more
Contact us:
Insilico Medicine, Inc.
Johns Hopkins University
9601 Medical Center Dr, Suite 127
Rockville, MD 20850
Phone: +1 240 641 62 66
Email: zhu@insilicomedicine.com
Johns Hopkins University
9601 Medical Center Dr, Suite 127
Rockville, MD 20850
Phone: +1 240 641 62 66
Email: zhu@insilicomedicine.com